Changeflow GovPing Pharma & Drug Safety Exercise risk assessment for lung cancer lobect...
Routine Notice Added Final

Exercise risk assessment for lung cancer lobectomy patients

Favicon for clinicaltrials.gov ClinicalTrials.gov
Detected April 3rd, 2026
Email

Summary

The National Library of Medicine registered a new clinical study (NCT07506889) on ClinicalTrials.gov investigating exercise risk assessment for patients undergoing lung cancer lobectomy. The registry entry documents study parameters, eligibility criteria, and investigators for this observational study.

What changed

ClinicalTrials.gov has registered a new clinical study, NCT07506889, titled 'Exercise risk assessment for lung cancer lobectomy patients.' This is an observational study examining exercise-related risks in patients scheduled for lung cancer lobectomy. The registry entry includes study design, inclusion/exclusion criteria, and investigator information.

This is an informational registry entry only and does not impose regulatory obligations. Healthcare providers and researchers may reference this study for awareness of ongoing clinical research in this area. No compliance actions, deadlines, or penalties are associated with this registration.

Source document (simplified)

Show glossary

Named provisions

Study Registration

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
NLM
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
NCT07506889
Docket
NCT07506889

Who this affects

Applies to
Healthcare providers Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical Trial Conduct
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Clinical Research

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ClinicalTrials.gov publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.